Ishikawa Y, Kakuta H, Fukushima M, Machida S, Fukuda S
Jpn J Surg. 1979 Sep;9(3):180-9. doi: 10.1007/BF02469419.
The prognosis of patients with advanced gastric cancer treated with non-curative resection is very poor. In order to improve patient prognosis, we have tried specific immunotherapy as an adjunct to surgery since January 1968. Sixty-two patients with gastric cancer underwent non-curative resection during the period of this study. Twenty-eight of these patients were treated with specific immunotherapy after surgery, and 34 patients received no additional therapy. The five year survival rate was 35 per cent in the former group, and zero in the latter. No significant difference in the degree of tumor extension and invasion was noted between the two patient groups. We concluded that specific immunotherapy as an adjunct to non-curative resection for advanced cancer is worthy of further study.
接受非根治性切除术治疗的晚期胃癌患者预后很差。为了改善患者预后，自1968年1月起，我们尝试将特异性免疫疗法作为手术的辅助治疗。在本研究期间，62例胃癌患者接受了非根治性切除术。其中28例患者术后接受了特异性免疫疗法，34例患者未接受额外治疗。前一组的五年生存率为35%，后一组为零。两组患者在肿瘤扩展和侵犯程度上没有显著差异。我们得出结论，特异性免疫疗法作为晚期癌症非根治性切除的辅助治疗值得进一步研究。
